Ipsen’s elafibranor has shown promise as a treatment for primary sclerosing cholangitis (PSC), a rare liver disease that ...

Expands Development Portfolio with Introduction of a Novel Program Targeting PSC – – Confirms Highly Specific Allosteric ACLY Inhibitor Shown to Reduce Liver Injury, Inflammation and Fibrosis Across ...

Rectify Pharmaceuticals, Inc., (“Rectify”) a biotechnology company pioneering positive functional modulators (PFMs) that ...

Healthcare providers look to rule out other liver disorders, such as biliary obstruction, hepatitis, primary sclerosing cholangitis (a chronic inflammation of the bile ducts), and liver disease ...

However, a recent randomized, controlled trial has surprisingly shown that the use of high-dose UDCA in patients with primary sclerosing cholangitis (PSC) may be harmful; adverse events ...

Primary sclerosing cholangitis (PSC) is an autoimmune injury in which infiltrating T lymphocytes are implicated in bile duct destruction through an as yet, unknown mechanism. In July Gut, Bo and ...

and primary sclerosing cholangitis (PSC). The most frequent ANA patterns in PBC sera are the 'speckled' (Figure 1), the multiple nuclear dots (MND; Figure 2), the rim-like/membranous (RL/M ...